Dr. Stephen D. Smith, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
825 Eastlake Ave E # G3-200
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Southern California Keck School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35086147
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 324
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 106 | 81 |
| Established patient office or other outpatient visit, 40-54 minutes | 69 | 43 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 45 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 35 | 34 |
| Hospital discharge day management, 30 minutes or less | 22 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 26 |
| Calquence (acalabrutinib maleate) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $2,315 in total to this clinician.
| Adc Therapeutics America, Inc. | $1,380 |
|---|---|
| Beone Medicines USA, Inc. | $800 |
| AstraZeneca Pharmaceuticals LP | $135 |
| Travel and Lodging | $1,118 |
|---|---|
| Consulting Fee | $800 |
| Food and Beverage | $397 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Sep 23, 2025 | Consulting Fee BRUKINSA · Oncology | $800 |
| Adc Therapeutics America, Inc. Oct 17, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO | $567 |
| Adc Therapeutics America, Inc. Oct 7, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO | $311 |
| Adc Therapeutics America, Inc. Oct 17, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO | $153 |
| Adc Therapeutics America, Inc. Oct 17, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO | $86.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 8 companies. The companies reported $1,390,983 in research payments for these studies, mostly to the institutions running them.
- Modified VR-CAP and Acalabrutinib As Induction Therapy for Transplant-Eligible Patients with Mantle Cell Lymphoma
AstraZeneca Pharmaceuticals LP - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - IIT_SMITH_ADCT-402-1
Adc Therapeutics America, Inc. - A phase 3 open-label, randomized study of LOXO-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naive mantle cell lymphoma (bruin MCL-321)
Eli Lilly and Company - OLD title: Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects with Relapsed Follicular and Diffuse Large B-Cell Lymphoma NEW Title: Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (M…
Merck Sharp & Dohme LLC - A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Beone Medicines Ltd. · Active, not recruiting · NCT04002297 - An openlabel phase 1 study to evaluate PF08046032 as monotherapy and part of combination therapy in participants with advanced malignancies
Pfizer Inc. - A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Acerta Pharma LLC - Polarix
Genentech, Inc. - Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.